Ergomed’s strategy is to become a global leader in pharmacovigilance and orphan drug development services by 2020. This refocusing of the business, communicated earlier in the year, moves Ergomed away from its reliance on the risk/reward profile of development deals and will ultimately result in a much better, more visible, and cash-generating story.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Building for growth
- Published:
16 Aug 2018 -
Author:
Elizabeth Klein -
Pages:
3
Ergomed’s strategy is to become a global leader in pharmacovigilance and orphan drug development services by 2020. This refocusing of the business, communicated earlier in the year, moves Ergomed away from its reliance on the risk/reward profile of development deals and will ultimately result in a much better, more visible, and cash-generating story.